Journal Article Epublish
PubMed: 40735470 DOI: 10.3389/fmolb.2025.1607352
Expression and clinical significance of S100A8/9 in adults with secondary phagocytic lymphohistiocytosis.
Front Mol Biosci 12:1607352
Authors: Ziwei Fang, Xin Gao, Limin Duan, Jujuan Wang, Tian Tian, Ji Xu, Yongqian Shu, Guangli Yin, Hongxia Qiu
Affiliations
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Abstract
Introduction
The study aimed to investigate the diagnostic and prognostic value of serum S100A8/9 levels with sHLHa, a high-mortality multiorgan inflammatory syndrome with no reliable clinical biomarkers, where calreticulin's role is unclear.
Methods
This was a study of 67 newly diagnosed sHLHa patients. 48 patients met criteria and were analyzed. ELISA detected S100A8/9 levels in patients and controls. The optimal classification threshold for S100A8/9 was determined to be 2.44 µg/mL by restricted cubic spline (RCS) curve analysis. Patients were categorized. Correlations, diagnostic efficacy, survival differences, and prognosis impacts were analyzed.
Results
Serum S100A8/9 levels in sHLHa patients were greater than in healthy controls. Various analyses showed its diagnostic and prognostic value. ANC<1.0 × 10 9/L and high S100A8/9 expression group were independent risk factors for poor prognosis in patients with sHLHa. It's correlated with liver function indicators and HScore.
Discussion
This study evaluates S100A8/9 in sHLHa diagnosis and prognosis. S100A8/9 levels are useful for differentiating patients, providing etiologic and survival info. They show a nonlinear positive correlation with survival and a threshold effect. Serum S100A8/9 levels offer potential biomarkers, and further studies are needed.
MeSH
Biomarkers, Diagnosis, Prognosis